Cargando…

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

BACKGROUND: Malignant mesothelioma (MM) carries a poor prognosis and response rates to palliative chemotherapy remain low. Identifying patients with MM that are unlikely to respond to chemotherapy could prevent futile treatments and improve patient quality of life. Studies have suggested that solubl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linch, Mark, Gennatas, Spyridon, Kazikin, Stanislav, Iqbal, Jhangir, Gunapala, Ranga, Priest, Kathryn, Severn, Joanne, Norton, Alison, Ayite, Bee, Bhosle, Jaishree, O’Brien, Mary, Popat, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182776/ https://www.ncbi.nlm.nih.gov/pubmed/25227779 http://dx.doi.org/10.1186/1471-2407-14-674

Ejemplares similares

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
por: Minchom, Anna, et al.
Publicado: (2019)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice
por: Abdelraouf, Fatma, et al.
Publicado: (2015)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres
por: Gennatas, S, et al.
Publicado: (2015)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Resolution of severe hyponatraemia is associated with improved survival in patients with cancer
por: Balachandran, Kirsty, et al.
Publicado: (2015)

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
por: He, Xiaoqing, et al.
Publicado: (2017)

Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma
por: Gennatas, Spyridon, et al.
Publicado: (2013)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells
por: Fujihira, Haruhiko, et al.
Publicado: (2021)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature
por: Lote, Hazel, et al.
Publicado: (2014)

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts
por: Macura, Sherrill L, et al.
Publicado: (2013)

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015)

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, Wanyuan, et al.
Publicado: (2020)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models
por: Alfaleh, Mohamed A., et al.
Publicado: (2017)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ijfiv28uab58m9u8degu4dc8q7